Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist that Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases.
Lawrence S EvansKatherine E LewisDaniel DeMonteJanhavi G BhandariLogan B GarrettJoseph L KuijperDaniel ArdourelMartin F WolfsonSusan DebrotSherri MudriKayla KleistLuana L GriffinLuAnne HebbRussell J SandersonNingXin WangMichelle SeabergAllison G ChunykJing YangYouji HongZahra MariaDavid J MessenheimerPamela M HollandStanford L PengMark W RixonStacey R DillonPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
Enhanced APRIL and BAFF inhibition by povetacicept leads to greater inhibition of B cell populations critical for autoantibody production versus WT TACI-Fc and CD20-, APRIL-, or BAFF-selective inhibitors. Potent, dual inhibition by povetacicept has the potential to significantly improve clinical outcomes in autoantibody-related autoimmune diseases. This article is protected by copyright. All rights reserved.